Use of mesenchymal stem cells for gene delivery to intracranialglioma

Sin Soo Jeun, Seong Muk Kim, Jung Yeon Lim, Chung Heon Ryu

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Virus-mediated gene therapies against brain tumors have been limited by the difficulty in tracking glioma cells infiltrating the brain parenchyma. Mesenchymal stem cells (MSCs) are particularly attractive cells for clinical use in cell-based therapies because they have tumor-targeting properties, can be easily isolated and expanded to the numbers required for use, and can be genetically manipulated with viral vectors. In addition, most of the replication-deficient adenoviral vectors that have been used to transduce MSCs are based on human Ad serotype 5 (Ad5). However, transduction of MSCs by conventional Ad5 vectors is inefficient, even when very high multiplicities of infection are used because MSCs do not express the cellular coxsackie-adenovirus receptor. This chapter describes in detail how such adenoviral transduction of MSCs mediated by cell-permeable peptides should be prepared and handled, and applied for the use of targeted therapeutic gene delivery into glioma by an in vitro migration assay and by in vivo injection of MSCs into the tumor mass or the opposite hemisphere of established human glioma in nude mice.

Original languageEnglish
Title of host publicationDrug Delivery to the Central Nervous System
EditorsKewal K. Jain
Pages277-290
Number of pages14
DOIs
StatePublished - 2010

Publication series

NameNeuromethods
Volume45
ISSN (Print)0893-2336
ISSN (Electronic)1940-6045

Keywords

  • Adenovirus
  • Cell-permeable peptides
  • Glioma
  • Mesenchymal stem cells
  • Umbilical cord blood

Fingerprint

Dive into the research topics of 'Use of mesenchymal stem cells for gene delivery to intracranialglioma'. Together they form a unique fingerprint.

Cite this